Open access · US-GOV
via ClinicalTrials.gov Clinical trial
SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
Authors not listed
University of Missouri-Columbia · 2024
Abstract
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-23 MST
Cite this
APA
Anonymous. (2024). SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging. <em>University of Missouri-Columbia</em>. https://clinicaltrials.gov/study/NCT06506422
Vancouver
Anonymous. SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging. University of Missouri-Columbia. 2024.
BibTeX
@misc{anon2024SGLTIn,
title = {SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging},
author = {Anonymous},
journal = {University of Missouri-Columbia},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature Medicine 2026
Preprint · OA
Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial
Guangzhou Patronus Biotech Co., Ltd. 2023
Open access · US-GOV
A Randomized, Blinded, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above(Negative for Antibody Against COVID-19)
Guangzhou Patronus Biotech Co., Ltd. 2022
Open access · US-GOV
A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above
Shanghai Zerun Biotechnology Co.,Ltd 2022
Open access · US-GOV
A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 60 Years and Above
Nature 2017
Open access · OA
RNA polymerase III limits longevity downstream of TORC1
Shanghai Zerun Biotechnology Co.,Ltd 2021
Open access · US-GOV